Immucor shares tumble with BioArray buy
This article was originally published in Clinica
Executive Summary
Shares in Immucor lost nearly a quarter of their value yesterday after investors learned that the company's earnings were to take a hit for -several years" as a result of its proposed acquisition of molecular diagnostics company BioArray Solutions.